NEW YORK, Jan. 12, 2015 /PRNewswire/ -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) – The liver is the largest organ in the human body and it is responsible for many crucial metabolic functions, including the regulation of lipid and sugar metabolism, protein production for proteins involved with blood clotting, and the purification of blood. There are over 100 described diseases of the human liver which can be very debilitating and life-threatening, if not effectively treated. Liver diseases can result from HCV, HBV (hepatitis B virus), obesity, chronic excessive alcohol use, or autoimmune diseases. According to the National Institutes of Health (NIH) an estimated 5.5 million Americans have chronic liver disease or cirrhosis, while according to the European Association for the Study of the Liver, 29 million Europeans have chronic liver disease. One company targeting this large potential market is Conatus Pharmaceuticals Inc.
Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. The company is focused on developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The company intends to develop emricasan in patients with liver cirrhosis, with varying levels of hepatic impairment, which are estimated to represent over 2 million diagnosed patients in the United States and the five major European markets. The company believes that emricasan has the potential to interrupt the progression of liver disease and potentially provide treatment options in multiple areas of liver disease.
A brief analyst report on CNAT that includes some positive and negative aspects of the company, can be viewed by using the following link at no cost:
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.